Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Oncol. May 24, 2024; 15(5): 635-643
Published online May 24, 2024. doi: 10.5306/wjco.v15.i5.635
Table 1 Baseline characteristics, n (%)
Variable
All (63)
Excellent efficacy group (42)
Poor efficacy group (21)
Age56 (51, 58)56 (50, 58)59 (50, 62)
Sex
    Male34 (54.7)20 (47.6)14 (66.7)
    Female29 (45.3)22 (52.4)7 (33.3)
ECOG-PS
    017 (27.0)12 (28.6)5 (23.8))
    139 (61.9)26 (61.9)13 (61.9)
    27 (11.1)4 (9.5)3 (14.3)
Disease status
    Unresectable 55 (87.3)38 (90.5)17 (81.0)
    Recurrent8 (12.7)4 (9.5)4 (19.0)
Number of organs involved
    140 (63.5)27 (64.3)13 (61.9)
    ≥ 223 (36.5)15 (35.7)8 (38.1)
HER2 status
    031 (49.2)17 (40.5)14 (66.7)
    115 (23.8)10 (23.8)5 (23.8)
    211 (17.5)11 (26.2)0 (0)
    Unmeasured6 (9.5)4 (9.5)2 (9.5)
CPS
    08 (12.7)2 (4.8)6 (28.6)
    1 ≤ CPS < 511 (17.5)7 (16.7)4 (19.0)
    5 ≤ CPS < 1012 (19.0)9 (21.4)3 (14.3)
    CPS ≥ 1021 (33.3)18 (42.9)3 (14.3)
    Unmeasured11 (17.5)6 (14.3)5 (23.8)
EBER
    Positive7 (11.1)6 (14.3)1 (4.8)
    Negative42 (66.7)26 (61.9)16 (76.2)
    Unmeasured14 (22.2)10 (23.8)4 (19.0)